SCHEMBL4469728

SCHEMBL4469728

CCCCc1cn2cc([N+](=O)[O-])ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 3/20 0.52
NPC1 O15118 2/20 0.52
LMNA P02545 2/20 0.52
GAA P10253 2/20 0.52
POLB P06746 2/20 0.52
STAT3 P40763 1/20 0.52
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
APP P05067 1/20 0.48
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CYP1A2 P05177 2/20 0.46
MAPT P10636 6/20 0.45
HPGD P15428 1/20 0.40
BLM P54132 1/20 0.40
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4477714 0.90 RAB9A (0.53) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL7986364 0.76 RAB9A (0.50) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL21835318 0.75 APP (0.42) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL23653213 0.74 RAB9A (0.66) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL16686955 0.73 MAPT (0.43) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL21835406 0.72 HRH3 (0.45) RAB9AALDH1A1NPC1GAAPOLB
SCHEMBL31191055 0.71 RAB9A (0.57) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL3776760 0.70 KDM4E (0.59) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL7986358 0.70 BCL9 (0.54) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA
SCHEMBL16686872 0.70 RAB9A (0.50) RAB9ASMN1; SMN2ALDH1A1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504412-B2 Imidazopyridine derivatives BANYU PHARMACEUTICALS, CO., LTD. (JP) 2009-03-17 US disclosed
US-20080200494-A1 Imidazopyridine Derivatives MSD K.K. (JP) 2008-08-21 US disclosed
EP-1657242-A1 IMIDAZOPYRIDINE DERIVATIVES Banyu Pharmaceutical Co., Ltd. (JP) 2006-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200494-A1 Imidazopyridine Derivatives MC1R, MC3R, MC5R RAB9A 1979/4885SMN1; SMN2 2050/4885ALDH1A1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.